Biodexa Pharmaceuticals (BDRX) said Monday that the US Food and Drug Administration granted fast track designation for eRapa to potentially treat familial adenomatous polyposis.
The designation helps facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
The company said it had received US FDA orphan drug designation for eRapa in familial adenomatous polyposis and intends to seek a similar designation in Europe.
Familial adenomatous polyposis universally leads to cancer of the colon and/or rectum if untreated, Biodexa said.
The company's shares were up more than 65% in recent trading.
Price: 6.75, Change: +2.68, Percent Change: +65.85
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。